Enzalutamide
Top View
- Fourth Quarter 2018 Update
- Investigator's Brochure Enzalutamide (MDV3100) Astellas Medivation, Inc
- CHMP Assessment Report
- Xtandi, INN-Enzalutamide
- Structure and Function of the Nuclear Receptor Superfamily and Current Targeted Therapies of Prostate Cancer
- XTANDI (Enzalutamide) 40 Mg Capsules Are Supplied As White to Off-White Oblong Soft Gelatin Capsules Imprinted in Black Ink with MDV
- Enzalutamide
- Most Common Medical Problems Are Listed Below
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Enzalutamide Inhibits Testosterone-Induced Growth Of
- Clinicaltrials.Gov Identifier: NCT02099864 Oregon Health & Science University OHSU Knight Cancer Institute OHSU Eirb Protocol #: 10241
- Human Blood-Based Exposure Levels of Persistent Organic Pollutant (POP
- (Nubeqa™), Apalutamide (Erleada™), Enzalutamide (Xtandi®), Abiraterone (Zytiga®, Yonsa®) EOCCO POLICY
- Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate In
- Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen
- Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
- Human Blood-Based Exposure Levels of Persistent Organic Pollutant (POP) T Mixtures Antagonise Androgen Receptor Transactivation and Translocation J
- Enzalutamide Therapy for Advanced Prostate Cancer: Efficacy, Resistance and Beyond